Utilizing chemistry to harness rna interference pathways for therapeutics: Chemically modified sirnas and antagomirs

Antisense Drug Technology: Principles, Strategies, and Applications, Second Edition

Volumn , Issue , 2007, Pages 437-464

  Manoharan, Muthiah ^a   Rajeev, Kallanthottathil G ^a  

^a ALNYLAM PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 67649290428     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (104)

1. MacRae, I. J.; Zhou, K.; Li, F.; Repic, A.; Brooks, A. N.; Cande, W. Z.; Adams, P. D. and Doudna, J. A. Structural basis for double-stranded RNA processing by Dicer. Science, 2006, 311, 195-198.
2. Elbashir, S. M.; Martinez, J.; Patkaniowska, A.; Lendeckel, W. and Tuschl, T. Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. EMBO J., 2001, 20, 6877-6888.
3. Martinez, J. and Tuschl, T. RISC is a 5′ phosphomonoester-producing RNA endonuclease. Genes Dev., 2004, 18, 975-980.
4. Wu, H.; Macleod, A. R.; Lima, W. F. and Crooke, S. T. Identification and partial purification of human double strand RNase activity. A novel terminating mechanism for oligoribonucleotide antisense drugs. J. Biol. Chem., 1998, 273, 2532-2542.
5. Rand, T. A.; Ginalski, K.; Grishin, N. V. and Wang, X. Biochemical identification of argonaute 2 as the sole protein required for RNA-induced silencing complex activity. Proc. Natl. Acad. Sci. USA, 2004, 101, 14385-14389.
6. Ma, J.-B.; Ye, K. and Patel, D. J. Structural basis for overhang-specific small interfering RNA recognition by the PAZ domain. Nature, 2004, 429, 318-322.
7. Parker, J. S.; Roe, S. M. and Barford, D. Structural insights into mRNA recognition from a PIWI domain-siRNA guide complex. Nature, 2005, 434, 663-666.
8. Ma, J.-B.; Yuan, Y.-R.; Meister, G.; Pei, Y.; Tuschl, T. and Patel, D. J. Structural basis for 5′-end-specific recognition of guide RNA by the A. fulgidus Piwi protein. Nature, 2005, 434, 666-670.
9. Matranga, C.; Tomari, Y.; Shin, C.; Bartel, D. P. and Zamore, P. D. Passenger-strand cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme complexes. Cell, 2005, 123, 607-620.
10. Rand, T. A.; Petersen, S.; Du, F. and Wang, X. Argonaute2 cleaves the anti-guide strand of siRNA during RISC activation. Cell, 2005, 123, 621-629.
11. Schwarz, D. S.; Hutvagner, G.; Haley, B. and Zamore, P. D. Evidence that siRNAs function as guides, not primers, in the Drosophila and human RNAi pathways. Mol. Cell, 2002, 10, 537-548.
12. Soutschek, J.; Akinc, A.; Bramlage, B.; Charisse, K.; Constien, R.; Donoghue, M.; Elbashir, S.; Geick, A.; Hadwiger, P.; Harborth, J.; John, M.; Kesavan, V.; Lavine, G.; Pandey, R. K.; Racie, T.; Rajeev, K. G.; Roehl, I.; Toudjarska, I.; Wang, G.; Wuschko, S.; Bumcrot, D.; Koteliansky, V.; Limmer, S.; Manoharan, M.; Vornlocher, H.-P. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature, 2004, 432, 173-178.
13. Harborth, J.; Elbashir, S. M.; Vandenburgh, K.; Manninga, H.; Scaringe, S. A.; Weber, K. and Tuschl, T. Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing. Antisense Nucl. Acid Drug Dev., 2003, 13, 83-105.
14. Amarzguioui, M.; Holen, T.; Babaie, E. and Prydz, H. Tolerance for mutations and chemical modifications in a siRNA. Nucl. Acids Res., 2003, 31, 589-595.
15. Freier, S. M. and Altmann, K.-H. The ups and downs of nucleic acid duplex stability: structure-stability studies on chemically-modified DNA:RNA duplexes. Nucl. Acids Res., 1997, 25, 4429-4443.
16. Hall, A. H. S.; Wan, J.; Shaughnessy, E. E.; Ramsay S., B. and Alexander, K. A. RNA interference using boranophosphate siRNAs: structure-activity relationships. Nucl. Acids Res., 2004, 32, 5991-6000.
17. Hall, A. H. S.; Wan, J.; Spesock, A.; Sergueeva, Z.; Shaw, B. R. and Alexander, K. A. High potency silencing by single-stranded boranophosphate siRNA. Nucl. Acids Res., 2006, 34, 2773-2781.
18. Prakash, T. P.; Kraynack, B.; Baker, B. F.; Swayze, E. E. and Bhat, B. RNA interference by 2′,5′-linked nucleic acid duplexes in mammalian cells. Bioorg. Med. Chem. Lett., 2006, 16, 3238-3240.
19. Morrissey, D. V.; Blanchard, K.; Shaw, L.; Jensen, K.; Lockridge, J. A.; Dickinson, B.; McSwiggen, J. A.; Vargeese, C.; Bowman, K.; Shaffer, C. S.; Polisky, B. A. and Zinnen, S. Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication. Hepatology, 2005, 41, 1349-1356.
20. Hamada, M.; Ohtsuka, T.; Kawaida, R.; Koizumi, M.; Morita, K.; Furukawa, H.; Imanishi, T.; Miyagishi, M. and Taira, K. Effects on RNA interference in gene expression (RNAi) in cultured mammalian cells of mismatches and the introduction of chemical modifications at the 3′-ends of siRNAs. Antisense Nucl. Acid Drug Dev., 2002, 12, 301-309.
21. Xu, Q.; Katkevica, D. and Rozners, E. Toward amide-modified RNA: synthesis of 3′-aminomethyl-5′-carboxy-3′,5′-dideoxy nucleosides. J. Org. Chem., 2006, 71, 5906-5913.
22. Allerson, C. R.; Sioufi, N.; Jarres, R.; Prakash, T. P.; Naik, N.; Berdeja, A.; Wanders, L.; Griffey, R. H.; Swayze, E. E. and Bhat, B. Fully 2′-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA. J. Med. Chem., 2005, 48, 901-904.
23. Hornung V.; Guenthner-Biller M.; Bourquin C.; Ablasser A.; Schlee M.; Uematsu S.; Noronha A.; Manoharan M.; Akira S.; de Fougerolles A.; Endres S. and Hartmann G. Sequence-specific potent induction of IFN-α by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat. Med., 2005, 11, 263-270.
24. Prakash, T. P.; Allerson, C. R.; Dande, P.; Vickers, T. A.; Sioufi, N.; Jarres, R.; Baker, B. F.; Swayze, E. E.; Griffey, R. H. and Bhat, B. Positional effect of chemical modifications on short interference RNA activity in mammalian cells. J. Med. Chem., 2005, 48, 4247-4253.
25. Hoshika, S.; Minakawa, N. and Matsuda, A. Synthesis and physical and physiological properties of 4′-thio-RNA: application to post-modification of RNA aptamer toward NF-κB. Nucl. Acids Res., 2004, 32, 3815-3825.
26. Haeberli, P.; Berger, I.; Pallan, P. S.; Egli, M. Syntheses of 4′-thioribonucleosides and thermodynamic stability and crystal structure of RNA oligomers with incorporated 4′-thiocytosine. Nucl. Acids Res., 2005, 33, 3965-3975.
27. Dande, P.; Prakash, T. P.; Sioufi, N.; Gaus, H.; Jarres, R.; Berdeja, A.; Swayze, E. E.; Griffey, R. H. and Bhat, B. Improving RNA interference in mammalian cells by 4′-thio-modified small interfering RNA (siRNA): effect on siRNA activity and nuclease stability when used in combination with 2′-O-alkyl modifications. J. Med. Chem., 2006, 49, 1624-1634.
28. Dowler, T.; Bergeron, D.; Tedeschi, A.-L.; Paquet, L.; Ferrari, N.; Damha, M. J. Improvements in siRNA properties mediated by 2′-deoxy-2′-fluoro-β-D-arabinonucleic acid (FANA). Nucl. Acids Res., 2006, 34, 1669-1675.
29. Parrish, S.; Fleenor, J.; Xu, S.; Mello, C.; Fire, A. Functional anatomy of a dsRNA trigger: differential requirement for the two trigger strands in RNA interference. Mol. Cell, 2000, 6, 1077-1087.
30. Chiu, Y.-L. and Rana, T. M. siRNA function in RNAi: a chemical modification analysis. RNA, 2003, 9, 1034-1048.
31. Xia, J.; Noronha, A.; Toudjarska, I.; Li, F.; Akinc, A.; Braich, R.; Frank-Kamenetsky, M.; Rajeev, K. G.; Egli, M. and Manoharan, M. Gene silencing activity of siRNAs with a ribo-difluorotoluyl nucleotide. ACS Chem. Biol., 2006, 1, 176-183.
32. Somoza, A.; Chelliserrykattil, J. and Kool, E. T. The roles of hydrogen bonding and sterics in RNA interference. Angew. Chem., Int. Ed. Engl., 2006, 45, 4994-4997.
33. 2-benzylguanosine limits the binding sites occupied by PKR. Chem. Bio. Chem., 2004, 5, 383-386.
34. Puthenveetil, S.; Whitby, L.; Ren, J.; Kelnar, K.; Krebs, J. F. and Beal, P. A. Controlling activation of the RNA-dependent protein kinase by siRNAs using site-specific chemical modification. Nucl. Acids Res., 2006, 34, 4900-4911.
35. Kariko, K.; Buckstein, M.; Ni, H. and Weissman, D. Suppression of RNA recognition by toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity, 2005, 23, 165-175.
36. Tuschl, T. Expanding small RNA interference. Nat. Biotechnol., 2002, 20, 446-448.
37. Elbashir, S. M.; Harborth, J.; Lendeckel, W.; Yalcin, A.; Weber, K. and Tuschl, T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature, 2001, 411, 494-498.
38. Czauderna, F.; Fechtner, M.; Dames, S.; Ayguen, H.; Klippel, A.; Pronk, G. J.; Giese, K. and Kaufmann, J. Structural variations and stabilizing modifications of synthetic siRNAs in mammalian cells. Nucl. Acids Res., 2003, 31, 2705-2716.
39. Koller, E.; Propp, S.; Murray, H.; Lima, W.; Bhat, B.; Prakash, T. P.; Allerson, C. R.; Swayze, E. E.; Marcusson, E. G. and Dean, N. M. Competition for RISC binding predicts in vitro potency of siRNA. Nucl. Acids Res., 2006, 34, 4467-4476.
40. Choung, S.; Kim, Y. J.; Kim, S.; Park, H.-O. and Choi, Y.-C. Chemical modification of siRNAs to improve serum stability without loss of efficacy. Biochem. Biophys. Res. Commun., 2006, 342, 919-927.
41. Bumcrot, D.; Manoharan, M.; Koteliansky, V.; Sah, D. W. Y. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat. Chem. Biol., 2006, 2, 711-719.
42. Schwarz, D. S.; Hutvagner, G.; Du, T.; Xu, Z.; Aronin, N. and Zamore, P. D. Asymmetry in the assembly of the RNAi enzyme complex. Cell, 2003, 115, 199-208.
43. Khvorova, A.; Reynolds, A. and Jayasena, S. D. Functional siRNAs and miRNAs exhibit strand bias. Cell, 2003, 115, 209-216.
44. Reynolds, A.; Leake, D.; Boese, Q.; Scaringe, S.; Marshall, W. S. and Khvorova, A. Rational siRNA design for RNA interference. Nat. Biotechnol., 2004, 22, 326-330.
45. Jackson, A. L.; Burchard, J.; Leake, D.; Reynolds, A.; Schelter, J.; Guo, J.; Johnson, J. M.; Lim, L.; Karpilow, J.; Nichols, K.; Marshall, W.; Khvorova, A. and Linsley, P. S. Position-specific chemical modification of siRNAs reduces “off-target” transcript silencing. RNA, 2006, 12, 1197-1205.
46. Sioud, M. Single-stranded small interfering RNA are more immunostimulatory than their double-stranded counterparts: a central role for 2′-hydroxyl uridines in immune responses. Eur. J. Immunol., 2006, 36, 1222-1230.
47. Judge, A. D.; Sood, V.; Shaw, J. R.; Fang, D.; McClintock, K. and MacLachlan, I. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat. Biotechnol., 2005, 23, 457-462.
48. Usman, N.; Pon, R. T. and Ogilvie, K. K. Preparation of ribonucleoside 3′-O-phosphoramidites and their application to the automated solid phase synthesis of oligonucleotides. Tetrahedron Lett., 1985, 26, 4567-4570.
49. Usman, N.; Ogilvie, K. K.; Jiang, M. Y. and Cedergren, R. J. The automated chemical synthesis of long oligoribuncleotides using 2′-O-silylated ribonucleoside 3′-O-phosphoramidites on a controlled-pore glass support: synthesis of a 43-nucleotide sequence similar to the 3′-half molecule of an Escherichia coli formylmethionine tRNA. J. Am. Chem. Soc., 1987, 109, 7845-7854.
50. Damha, M. J. and Ogilvie, K. K. Synthesis and spectroscopic analysis of branched RNA fragments:messenger RNA splicing intermediates. J. Org. Chem., 1988, 53, 3710-3722.
51. Ogilvie, K. K.; Usman, N.; Nicoghosian, K.; Cedergren, R. J. Total chemical synthesis of a 77-nucleotide-long RNA sequence having methionine-acceptance activity. Proc. Natl. Acad. Sci. USA, 1988, 85, 5764-5768.
52. Kierzek, R.; Rozek, M. and Markiewicz, W. T. Some steric aspects of synthesis of oligoribonucleotides by phosphoramidite approach on solid support. Bull. Polish Acad. Sci., Chem., 1988, 35, 507-516.
53. Scaringe, S. A.; Francklyn, C. and Usman, N. Chemical synthesis of biologically active oligoribonucleotides using β-cyanoethyl protected ribonucleoside phosphoramidites. Nucl. Acids Res., 1990, 18, 5433-5441.
54. Iwai, S.; Sasaki, T. and Ohtsuka, E. Large scale synthesis of oligoribonucleotides on a solid support:synthesis of a catalytic RNA duplex. Tetrahedron, 1990, 46, 6673-6688.
55. Usman, N. and Cedergren, R. Exploiting the chemical synthesis of RNA. Trends Biochem. Sci., 1992, 17, 334-339.
56. Stawinski, J.; Stroemberg, R.; Thelin, M. and Westman, E. Evaluation of the use of the tert-butyldimethylsilyl group for 2′-protection in RNA-synthesis via the H-phosphonate approach. Nucleosides Nucleotides, 1988, 7, 779-782.
57. Stawinski, J.; Stroemberg, R.; Thelin, M. and Westman, E. Studies on the t-butyldimethylsilyl group as 2′-O-protection in oligoribonucleotide synthesis via the H-phosphonate approach. Nucl. Acids Res., 1988, 16, 9285-9298.
58. Gasparutto, D.; Livache, T.; Bazin, H.; Duplaa, A. M.; Guy, A.; Khorlin, A.; Molko, D.; Roget, A.; Teoule, R. Chemical synthesis of a biologically active natural tRNA with its minor bases. Nucl. Acids Res., 1992, 20, 5159-5166.
59. Westman, E. and Stroemberg, R. Removal of t-butyldimethylsilyl protection in RNA-synthesis. Triethylamine trihydrofluoride (TEA, 3HF) is a more reliable alternative to tetrabutylammonium fluoride (TBAF). Nucl. Acids Res., 1994, 22, 2430-2431.
60. Song, Q. and Jones, R. A. Use of silyl ethers as fluoride scavengers in RNA synthesis. Tetrahedron Lett., 1999, 40, 4653-4654.
61. Manoharan, M.; Jung, M. E.; Rajeev, K. G.; Pandey, R. K. and Wang, G. Process and phosphoramidation reagents for oligonucleotide synthesis and purification. PCT Int. Appl., 2005, 181 (WO 2005097817 A2 20051020).
62. Wang, G.; Charisse, K.; Zedalis, W.; Nechev, L. and Manoharan, M. Novel processes for synthesis of RNA oligonucleotides. Abstracts of Papers, 231st ACS National Meeting, Atlanta, GA, United States, March 26-30, 2006, CARB-070.
63. Pitsch, S.; Weiss, P. A.; Wu, X.; Ackermann, D. and Honegger, T. Fast and reliable automated synthesis of RNA and partially 2′-O-protected precursors (“caged RNA”) based on two novel, orthogonal 2′-Oprotecting groups. Helv. Chim. Acta, 1999, 82, 1753-1761.
64. Semenyuk, A.; Foeldesi, A.; Johansson, T.; Estmer-Nilsson, C.; Blomgren, P.; Braennvall, M.; Kirsebom, L. A. and Kwiatkowski, M. Synthesis of RNA using 2′-O-DTM protection. J. Am. Chem. Soc., 2006, 128, 12356-12357.
65. Ohgi, T.; Masutomi, Y.; Ishiyama, K.; Kitagawa, H.; Shiba, Y. and Yano, J. A New RNA synthetic method with a 2′-O-(2-cyanoethoxymethyl) protecting group. Org. Lett., 2005, 7, 3477-3480.
66. Capaldi, D. C. and Reese, C. B. Use of the 1-(2-fluorophenyl)-4-methoxypiperidin-4-yl (Fpmp) and related protecting groups in oligoribonucleotide synthesis: stability of internucleotide linkages to aqueous acid. Nucl. Acids Res., 1994, 22, 2209-2216.
67. Lloyd, W.; Reese, C. B.; Song, Q.; Vandersteen, A. M.; Visintin, C. and Zhang, P.-Z. Some observations relating to the use of 1-aryl-4-alkoxypiperidin-4-yl groups for the protection of the 2′-hydroxy functions in the chemical synthesis of oligoribonucleotides. Perkin 1, 2000, 2, 165-176.
68. Scaringe, S. A.; Wincott, F. E. and Caruthers, M. H. Novel RNA synthesis method using 5′-O-silyl-2′-Oorthoester protecting groups. J. Am. Chem. Soc., 1998, 120, 11820-11821.
69. Dahl, B. H.; Bjergaarde, K.; Henriksen, L. and Dahl, O. A highly reactive, odorless substitute for thiophenol/triethylamine as a deprotection reagent in the synthesis of oligonucleotides and their analogs. Acta Chem. Scand. 1990, 44, 639-641.
70. Parey, N.; Baraguey, C.; Vasseur, J.-J. and Debart, F. First evaluation of acyloxymethyl or acylthiomethyl groups as biolabile 2′-O-protections of RNA. Org. Lett., 2006, 8, 3869-3872.
71. Lorenz, C.; Hadwiger, P.; John, M.; Vornlocher, H.-P. and Unverzagt, C. Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells. Bioorg. Med. Chem. Lett., 2004, 14, 4975-4977.
72. Crooke, S. T.; Graham, M. J.; Zukerman, J. E.; Brooks, D.; Conklin, B. S.; Cummins, L. L.; Greig, M. J.; Guinosso, C. J.; Kornburst, D.; et al. Pharmacokinetic properties of several novel oligonucleotide analogs in mice. J. Pharmacol. Exp. Ther., 1996, 277, 923-937.
73. Henry, S. P.; Zuckerman, J. E.; Rojko, J.; Hall, W. C.; Harman, R. J.; Kitchen, D. and Crooke, S. T. Toxicological properties of several novel oligonucleotide analogs in mice. Anti-Cancer Drug Des., 1997, 12, 1-14.
74. McNamara, J. O., II; Andrechek, E. R.; Wang, Y.; Viles, K. D.; Rempel, R. E.; Gilboa, E.; Sullenger, B. A. and Giangrande, P. H. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat. Biotechnol., 2006, 24, 1005-1015.
75. Chu, T. C.; Twu, K. Y.; Ellington, A. D. and Levy, M. Aptamer mediated siRNA delivery. Nucl. Acids Res., 2006, 34, e73/1-e73/6.
76. Pal, A.; Ahmad, A.; Khan, S.; Sakabe, I.; Zhang, C.; Kasid, U. N. and Ahmad, I. Systemic delivery of RafsiRNA using cationic cardiolipin liposomes silences Raf-1 expression and inhibits tumor growth in xenograft model of human prostate cancer. Int. J. Oncol., 2005, 26, 1087-1091.
77. Urban-Klein, B.; Werth, S.; Abuharbeid, S.; Czubayko, F. and Aigner, A. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther., 2005, 12, 461-466.
78. Morrissey, D. V.; Lockridge, J. A.; Shaw, L.; Blanchard, K.; Jensen, K.; Breen, W.; Hartsough, K.; Machemer, L.; Radka, S.; Jadhav, V.; Vaish, N.; Zinnen, S.; Vargeese, C.; Bowman, K.; Shaffer, C. S.; Jeffs, L. B.; Judge, A.; MacLachlan, I. and Polisky, B. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat. Biotechnol., 2005, 23, 1002-1007.
79. Zimmermann, T. S.; Lee, A. C. H.; Akinc, A.; Bramlage, B.; Bumcrot, D.; Fedoruk, M. N.; Harborth, J.; Heyes, J. A.; Jeffs, L. B.; John, M.; Judge, A. D.; Lam, K.; McClintock, K.; Nechev, L. V.; Palmer, L. R.; Racie, T.; Roehl, I.; Seiffert, S.; Shanmugam, S.; Sood, V.; Soutschek, J.; Toudjarska, I.; Wheat, A. J.; Yaworski, E.; Zedalis, W.; Koteliansky, V.; Manoharan, M.; Vornlocher, H.-P. and MacLachlan, I. RNAimediated gene silencing in non-human primates. Nature, 2006, 441, 111-114.
80. Yano, J.; Hirabayashi, K.; Nakagawa, S.-i.; Yamaguchi, T.; Nogawa, M.; Kashimori, I.; Naito, H.; Kitagawa, H.; Ishiyama, K.; Ohgi, T. and Irimura, T. Antitumor activity of small interfering RNA/cationic liposome complex in mouse models of cancer. Clin. Cancer Res., 2004, 10, 7721-7726.
81. Schiffelers, R. M.; Ansari, A.; Xu, J.; Zhou, Q.; Tang, Q.; Storm, G.; Molema, G.; Lu, P. Y.; Scaria, P. V. and Woodle, M. C. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucl. Acids Res., 2004, 32, e149/1-e149/10.
82. Zhang Z.; Yang X.; Zhang Y.; Zeng B.; Wang S.; Zhu T.; Roden R. B S; Chen Y. and Yang R. Delivery of telomerase reverse transcriptase small interfering RNA in complex with positively charged single-walled carbon nanotubes suppresses tumor growth. Clin. Cancer Res., 2006, 12, 4933-4939.
83. Song, E.; Zhu, P.; Lee, S.-K.; Chowdhury, D.; Kussman, S.; Dykxhoorn, D. M.; Feng, Y.; Palliser, D.; Weiner, D. B.; Shankar, P.; Marasco, W. A. and Lieberman, J. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat. Biotechnol., 2005, 23, 709-717.
84. Hu-Lieskovan, S.; Heidel, J. D.; Bartlett, D. W.; Davis, M. E. and Triche, T. J. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing’s sarcoma. Cancer Res., 2005, 65, 8984-8992.
85. Santel, A.; Aleku, M.; Keil, O.; Endruschat, J.; Esche, V.; Fisch, G.; Dames, S.; Loeffler, K.; Fechtner, M.; Arnold, W.; Giese, K.; Klippel, A. and Kaufmann, J. A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium. Gene Ther., 2006, 13, 1222-1234.
86. Santel, A.; Aleku, M.; Keil, O.; Endruschat, J.; Esche, V.; Durieux, B.; Loeffler, K.; Fechtner, M.; Roehl, T.; Fisch, G.; Dames, S.; Arnold, W.; Giese, K.; Klippel, A. and Kaufmann, J. RNA interference in the mouse vascular endothelium by systemic administration of siRNA-lipoplexes for cancer therapy. Gene Ther., 2006, 13, 1360-1370.
87. Wu, H.; Xu, H.; Miraglia, L. J. and Crooke, S. T. Human RNase III is a 160-kDa protein involved in preribosomal RNA processing. J. Biol. Chem., 2000, 275, 36957-36965.
88. Ouellet D. L; Perron M. P; Gobeil L.-A.; Plante P. and Provost P. MicroRNAs in gene regulation: when the smallest governs it all. J. Biomed. Biotechnol., 2006, 2006, 69616.
89. Sarnow, P.; Jopling, C. L.; Norman, K. L.; Schuetz, S. and Wehner, K. A. MicroRNAs: expression, avoidance and subversion by vertebrate viruses. Nat. Rev. Microbiol., 2006, 4, 651-659.
90. Wightman, B.; Ha, I. and Ruvkun, G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell, 1993, 75, 855-862.
91. Yekta, S.; Shih, I-h. and Bartel, D. P. MicroRNA-directed cleavage of HOXB8 mRNA. Science, 2004, 304, 594-596.
92. Hutvagner, G. and Zamore, P. D. A microRNA in a multiple-turnover RNAi enzyme complex. Science, 2002, 297, 2056-2060.
93. Zeng, Y. Yi, R. and Cullen, B. R. MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms. Proc. Natl. Acad. Sci. USA, 2003, 100, 9779-9784.
94. Lewis, B. P.; Burge, C. B. and Bartel, D. P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell, 2005, 120, 15-20.
95. Jin, P.; Zarnescu, D. C.; Ceman, S.; Nakamoto, M.; Mowrey, J.; Jongens, T. A.; Nelson, D. L.; Moses, K. and Warren, S. T. Biochemical and genetic interaction between the fragile X mental retardation protein and the microRNA pathway. Nat. Neurosci., 2004, 7, 113-117.
96. Weiler, J.; Hunziker, J. and Hall, J. Anti-miRNA oligonucleotides (AMOs): ammunition to target miRNAs implicated in human disease? Gene Ther., 2006, 13, 496-502.
97. Poy, M. N.; Eliasson, L.; Krutzfeldt, J.; Kuwajima, S.; Ma, X.; MacDonald, P. E.; Pfeffer, S.; Tuschl, T.; Rajewsky, N.; Rorsman, P. and Stoffel, M. A pancreatic islet-specific microRNA regulates insulin secretion. Nature, 2004, 432, 226-230.
98. Kruetzfeldt, J.; Rajewsky, N.; Braich, R.; Rajeev, K. G.; Tuschl, T.; Manoharan, M. and Stoffel, M. Silencing of microRNAs in vivo with ‘antagomirs’. Nature, 2005, 438, 685-689.
99. Esau, C.; Davis, S.; Murray, S. F.; Yu, X. X.; Pandey, S. K.; Pear, M.; Watts, L.; Booten, S. L.; Graham, M.; McKay, R.; Subramaniam, A.; Propp, S.; Lollo, B. A.; Freier, S.; Bennett, C. F.; Bhanot, S. and Monia, B. P. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab., 2006, 3, 87-98.
100. Sullivan, C. S.; Grundhoff, A. T.; Tevethia, S.; Pipas, J. M. and Ganem, D. SV40-encoded microRNAs regulate viral gene expression and reduce susceptibility to cytotoxic T cells. Nature, 2005, 435, 682-686.
101. Lakatos, L.; Szittya, G.; Silhavy, D. and Burgyan, J. Molecular mechanism of RNA silencing suppression mediated by p19 protein of tombusviruses. EMBO J., 2004, 23, 876-884.
102. Jopling, C. L.; Yi, M.; Lancaster, A. M.; Lemon, S. M. and Sarnow, P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science, 2005, 309, 1577-1581.
103. Gupta, A.; Gartner, J. J.; Sethupathy, P.; Hatzigeorgiou, A. G. and Fraser, N. W. Anti-apoptotic function of a microRNA encoded by the HSV-1 latency-associated transcript. Nature, 2006, 442, 82-85.
104. Fire, A.; Xu, S.; Montgomery, M. K.; Kostas, S. A.; Driver, S. E. and Mello, C. C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans, Nature, 1998, 391, 806-811.